Cannabinol

CBN binds CB1 and CB2 cannabinoid receptors with much lower affinity than THC, resulting in significantly reduced psychoactivity. It has weak partial agonist activity at CB1 receptors and stronger activity at CB2 receptors, which may contribute to peripheral effects rather than the central euphoria associated with THC. The most common consumer use of CBN is sleep support. The basis for this is largely anecdotal and historical (associated with the sedative effect attributed to aged cannabis), but there is limited rigorous clinical evidence for CBN's sleep effects in isolation. Preclinical studies suggest possible anti-inflammatory, antibacterial, and appetite-stimulating effects. CBN is fat-soluble; bioavailability is variable and improved by lipid co-administration.

There is no RDA. Consumer CBN products typically provide 2.5 to 30 mg per dose, often combined with CBD, melatonin, or sleep-supporting botanicals. Optimal dosing is not well established by clinical research.

CBN is typically taken 30 to 60 minutes before bed for sleep support. Sublingual oils have faster onset (15 to 30 minutes); capsules and edibles take longer (1 to 2 hours) but provide longer duration. Take with food (especially fat) for better absorption.

Generally well tolerated at consumer doses. Common side effects include drowsiness, dry mouth, mild changes in mood or appetite. CBN may cause subtle cognitive impairment at higher doses. Long-term safety data are limited. The supplement market for cannabinoids has quality and labeling accuracy issues; use only third-party tested products. Regulatory status varies by jurisdiction.

Like other cannabinoids, CBN may inhibit cytochrome P450 enzymes (CYP3A4, CYP2D6), potentially affecting metabolism of many medications. May enhance sedative effects of CNS depressants. Limited human interaction data.